Aplagon is also planning for 2026 a Phase 2 clinical trial for arteriovenous fistula (AVF) maturation failure in Europe, following the successful completion of its Phase 1 AVF trial. The study ...

Aplagon has dosed the first patient in its phase 2a HEALING clinical trial evaluating APAC, a first‑in‑class treatment for thrombo‑inflammatory diseases, in people with peripheral arterial occlusive ...

The vast majority of patients presenting with type 1 NSTEMI undergo invasive coronary angiography in the US, with most receiving PCI, according to an analysis presented this week at CRT 2026. But as ...

At 3 years, Agent still outshined uncoated balloons. Registry data show rapid uptake of the DCB in the year after its FDA approval.